Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome?

Archives of Medical Science

Volumn 8, Issue 3, 2012, Pages 449-454

  Babińska, Magdalena ^a   Holecki, Michał ^a   Prochaczek, Fryderyk ^a   Owczarek, Aleksander ^a   Kokocinśka, Danuta ^a   Chudek, Jerzy ^a   Wieçek, Andrzej ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Acute coronary syndrome; Urotensin II

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MB; CREATININE; TROPONIN C; UROTENSIN II;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL;

EID: 84863941090     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.29400     Document Type: Article

References (23)

1. Pearson D, Shively JE, Clark BR, et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci U S A 1980; 77: 5021-4. (Pubitemid 11236553)
2. Chen YH, Yandle TG, Richards AM, Palmer SC. Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release. Clin Chem 2009; 55: 2040-8.
3. Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000; 131: 1262-74.
4. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004; 25: 1767-74. (Pubitemid 39346219)
5. Russell FD, Meyers D, Galbraith AJ, et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003; 285: 1576-81.
6. Douglas SA, Dhanak D, Johns DG. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004; 25: 76-85. (Pubitemid 38183393)
7. Zhu YC, Zhu YZ, Moore PK. The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol 2006; 148: 884-901. (Pubitemid 44543606)
8. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 2001; 132: 5-9. (Pubitemid 32128427)
9. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci 2003; 104: 1-5. (Pubitemid 36249917)
10. Kemp W, Krum H, Colman J, et al. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int 2007; 27: 1232-9. (Pubitemid 47543152)
11. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P, Malatino L. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int 2006; 69: 1253-8.
12. Khan SQ, Bhandari SS, Quinn P, Davies JE, Ng LL. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 2007; 117: 323-8. (Pubitemid 46507623)
13. Joyal D, Huynh T, Aiyar N, Guida B, Douglas S, Giaid A. Urotensin-II levels in acute coronary syndromes. Int J Cardiol 2006; 108: 31-5. (Pubitemid 43324903)
14. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002; 359: 1990-7. (Pubitemid 34663713)
15. Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 2001; 286: 1356-9. (Pubitemid 33015527)
16. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-8. (Pubitemid 8066109)
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70. (Pubitemid 29135798)
18. Rdzanek A, Filipiak K, Karpiński G, Grabowski M, Opolski G. Exercise urotensin II Dynamics In myocardial infarction survivors with and without hypertension. Int J Cardiol 2006, 110: 175-8. (Pubitemid 43767107)
19. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004; 22: 1341-4. (Pubitemid 38888080)
20. Russell F. Urotensin II in cardiovascular regulation. Vasc Health Risk Manag 2008; 4: 775-85.
21. Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000; 130: 1865-70. (Pubitemid 30655798)
22. Douglas S, Ashton D, Sauermelch C, et al. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primates. J Cardiovasc Pharmacol 2000; 26: 163-6.
23. Stirrat A, Gallagher M, Douglas A, et al. Potent vasodilatator response to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001; 280: 925-8.